Participated · Series A · Jul 2026

Brenus Pharma is advancing an off-the-shelf platform in immuno-oncology that mimics tumor protein expression to make tumors visible to the immune system. Its lead clinical-stage asset is STC-1010 (NCT06934538), targeting MSS metastatic colorectal cancer, and recent execution across clinical, regulatory and business development milestones has been highlighted by the company. Brenus positions its technology for multi-asset expansion and plans to use new capital to complete the Phase I program for STC-1010 and to advance its next drug candidate. The company has raised a total of €38 million since inception following the €11 million Series A extension. The firm announced the financing from Lyon, France and continues engaging both existing and new international investors to support its development plans.

Participated · Seed · Mar 2026

Vertical Compute is a Belgian semiconductor startup engineering chiplets in which vertical memory stacks are integrated directly on top of compute logic during 300 mm wafer fabrication. This 3D architecture restructures on-chip data flow and addresses the longstanding “memory wall,” cutting latency and energy use compared with traditional 2D memory layouts. The company has already produced its first test chip demonstrating the concept. With a headcount of 25, Vertical Compute now plans to shift from validation to the commercial rollout of its chiplets for emerging AI platforms. Financially, the startup has secured €57 million to date, including a €20 million round in 2022 and the latest €37 million raise. No revenue figures have been disclosed, but the fresh capital provides runway for scaling manufacturing and bringing its products to market.

Participated · Seed · Jan 2026

Enodia Therapeutics is building a small-molecule drug discovery platform that selectively modulates the SEC61 translocon, enabling degradation of secreted and membrane proteins before they leave the endoplasmic reticulum. The approach blends a tailored library of signal-peptide cell lines, proteomics-based secretome analysis and machine-learning models to achieve unprecedented selectivity in targeted protein degradation. Originating from research at the Institut Pasteur and incubated by Argobio Studio, the company is initially pursuing inflammatory and autoimmune disease programs while exploring applications in oncology and viral infections. Management intends to advance the lead program to preclinical candidate selection within the next twelve months, marking a key value inflection point. The platform leverages several families of well-characterized inhibitors, offering the potential to unlock previously undruggable targets. Enodia’s strategy emphasizes repeated translation of complex SEC61 biology into differentiated drug candidates and broad partnering potential. The recent seed financing provides the capital to validate the platform and expand the early pipeline. No commercial revenue or clinical-stage assets have been disclosed to date.

Participated · Equity · Sep 2025

Founded in 2015, Belgium-headquartered Sunrise Group pairs FDA-cleared sleep-diagnostic hardware—most notably its mandibular movement sensor—with a full-stack software platform to power Dreem Health, its U.S. digital sleep clinic. Patients connect online with licensed sleep specialists who diagnose and treat conditions such as sleep apnea and insomnia entirely from home and with insurance coverage. Sunrise has regulatory clearances in all 50 states, contracts with payors that collectively insure more than 170 million Americans, and a clinical network exceeding 500 referring providers. The company operates with a team of 80+ clinicians, engineers, and researchers and positions its integrated tech-and-care model as a scalable answer to the severe shortage of sleep physicians. Revenue figures were not disclosed, but the firm secured a $29 million capital infusion to fund nationwide expansion and next-generation hardware and software development. Future plans include enlarging clinical services, accelerating U.S. market penetration, and continuing R&D on detection, monitoring, and treatment technologies for a broad range of sleep disorders.

Participated · Series A · Nov 2024

ATB Therapeutics develops first‑in‑class biologics that integrate novel enzymatic and cytotoxic functionalities into targeted antibodies. Its proprietary ATBioFarm platform enables scalable, single‑step production of antibodies that combine multiple targeting and killing domains. The company is advancing a pipeline of ‘‘weaponized’’ antibodies intended to improve efficacy and safety compared with traditional conjugates. Proceeds from the recent financing are intended to accelerate clinical development of oncology and immunology candidates and to expand the ATBioFarm technology. ATB will extend research and development operations to Ghent and continue work in Marche‑en‑Famenne, where it is setting up a pilot manufacturing facility. Leadership was strengthened as industry veteran Mark Throsby joined as Executive Chair and investor partners joined the board.